FGFR2 and cholangiocarcinoma: To quantitate the percentages of bile duct cells that were immuno-positive for CEBPB or FGFR2 in CC and HB livers, we counted all the bile duct cells and the CEBPB immuno-positive (CEBPB+ve) or FGFR2 immuno-positive (FGFR2+ve) bile duct cells on CC (n = 35) and HB (n = 10) liver sections (tumor and non-tumor).